Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of “Moderate Buy” from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $39.00.

A number of research firms have recently commented on ARTV. Wedbush lifted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Needham & Company LLC reissued a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th.

Insider Transactions at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, COO Jennifer Bush sold 8,790 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total transaction of $79,197.90. Following the sale, the chief operating officer directly owned 337,920 shares of the company’s stock, valued at $3,044,659.20. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Fred Aslan sold 27,116 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the transaction, the chief executive officer owned 1,535,082 shares of the company’s stock, valued at $13,831,088.82. This represents a 1.74% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders purchased 9,534,631 shares of company stock valued at $104,042,163 and sold 53,040 shares valued at $477,890. Corporate insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of ARTV. Citadel Advisors LLC grew its stake in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Artiva Biotherapeutics in the fourth quarter worth $341,000. Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter worth $67,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Artiva Biotherapeutics in the third quarter worth $112,000.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock remained flat at $9.61 during midday trading on Friday. 435,839 shares of the company traded hands, compared to its average volume of 703,898. Artiva Biotherapeutics has a 1-year low of $1.55 and a 1-year high of $14.53. The stock’s 50-day simple moving average is $9.12 and its 200-day simple moving average is $6.78. The company has a market capitalization of $237.56 million, a PE ratio of -2.71 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts predict that Artiva Biotherapeutics will post -2.45 EPS for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.